Okazaki Jason A 4

What Happened Jason Okazaki, CEO, President and Director of Assembly Biosciences (ASMB), was granted 94,250 restricted stock units (RSUs) on March 29, 2026. The RSUs were reported as an award (Form 4 code A) with an acquisition price of $0.00 (the filing reports $0 for the grant). This is a compensation award — not an open-market purchase or sale.

Key Details

• Transaction date: 2026-03-29; Form 4 filed: 2026-03-31 (filed within the usual 2-business-day window).
• Grant size and price: 94,250 RSUs; acquisition price reported $0.00.
• Vesting: RSUs vest in four approximately equal installments on March 29 of 2027, 2028, 2029 and 2030, subject to continuous service.
• Contingency: The RSUs represent 65% of Okazaki’s annual equity grant; the remaining 35% is contingent on stockholder approval of an amendment to the company’s 2018 Stock Incentive Plan to increase authorized shares.
• Holdings note: The filing notes inclusion of 2,909 shares acquired under the company’s Employee Stock Purchase Plan (ESPP) on May 14, 2025. The total shares beneficially owned after this grant are not specified in the provided data.
• Transaction code: A = Award/Grant. This is a compensation grant rather than a market transaction.

Context RSUs are time-vested compensation: they create future ownership only if the executive remains in service through each vesting date (or unless other acceleration provisions apply). The 35% portion is not guaranteed until shareholders approve the plan amendment, so only the 65% portion is currently unconditional under the grant terms. Such grants are routine elements of executive pay and do not by themselves indicate a buy/sell sentiment.